A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs KSI 301 (Primary)
- Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Kodiak Sciences
- 08 Feb 2019 According to a Kodiak Sciences media release, an update about the trial will be presented at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.
- 31 Dec 2018 Status changed from planning to recruiting.
- 03 Dec 2018 New trial record